Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19507326 | 0.81 | CA1 (0.32) | CA1CA2CA4 | |
| SCHEMBL22014631 | 0.76 | — | — | |
| SCHEMBL7908206 | 0.72 | ALDH1A1 (0.43) | POLBALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL31569104 | 0.72 | CYP3A4 (0.43) | POLBALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL21603437 | 0.71 | CYP3A4 (0.39) | POLBALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL21603389 | 0.70 | ALDH1A1 (0.42) | POLBALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL29824949 | 0.70 | ALDH1A1 (0.42) | POLBALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL19475225 | 0.68 | — | — | |
| SCHEMBL23029213 | 0.68 | ADORA2B (0.40) | — | |
| SCHEMBL21852776 | 0.68 | CYP3A4 (0.38) | POLBALDH1A1TP53CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130352-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-05-06 | — | — | US | disclosed |
| WO-2019243533-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130352-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | POLB 402/4885ALDH1A1 3839/4885TP53 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.